Additional file 4 of GASDERMIN D-mediated pyroptosis as a therapeutic target in TAU-dependent frontotemporal dementia mouse model

Additional file 4 (Supplementary Figure 4. GSDMD deficiency does not alter TAU levels in AAV-TAUP301L mice and DMF treatment reduces TAU phosphorylation in hippocampus of both tauopathy mouse models. Immunostaining of total TAU (red) and p-TAUSer202,Thr205 (green) in the CA3 region of (A) Gsdmd+/+ and Gsdmd-/- mice that overexpress TAUP301L on the ipsilateral side, (C) AAV-TAUP301L mice treated with VEH or DMF and (E) 8-month-old Tg-TAUP301S mice and WT mice treated with VEH or DMF. Quantification of p-TAUSer202,Thr205/total TAU ratio of (B) Gsdmd+/+ and Gsdmd-/- mice that overexpress TAUP301L on the ipsilateral side, (D) AAV-TAUP301L mice treated with VEH or DMF and (F) 8-month-old Tg-TAUP301S mice and WT mice treated with VEH or DMF. Bars represent the mean of 4-6 samples ±SEM. Asterisks indicate significant differences of ***p